Combination of the digital therapeutic glucura with intermittent continuous glucose monitoring (CGM) significantly improved HbA1c reduction compared to CGM with standard care alone in non-insulin-treated type 2 diabetes.
Glucura users achieved higher rates of stringent glycaemic targets (HbA1c <7.0% and <6.5%) and experienced greater weight loss.
Beyond metabolic benefits, glucura improved mental health and reduced diabetes-related distress without serious adverse events.
